within Pharmacolibrary.Drugs.ATC.A;

model A03AX11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.2,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Caroverine is a spasmolytic drug with anticholinergic and calcium channel blocking properties. It has been used in the treatment of smooth muscle spasms, gastrointestinal disorders, and has also been investigated for the treatment of tinnitus. Caroverine is not widely approved or in current mainstream clinical use in many countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies in humans providing model parameters could be identified. The following parameters are provided as estimates based on general pharmacokinetic knowledge for small molecule, basic drugs of similar molecular size and intended oral and intravenous use.</p><h4>References</h4><ol><li>Zhiqiang Chen, Maoli Duan, Howsung Lee, Runsheng Ruan, Mats Ulfendahl,Pharmacokinetics of caroverine in the inner ear and its effects on cochlear function after systemic and local administrations in Guinea pigs.,Audiology & neuro-otology,2003<a href='https://pubmed.ncbi.nlm.nih.gov/12566692/'>https://pubmed.ncbi.nlm.nih.gov/12566692/</a></li><li>Elmar Oestreicher, Klaus Ehrenberger, Dominik Felix,Different action of memantine and caroverine on glutamatergic transmission in the mammalian cochlea.,Advances in oto-rhino-laryngology,2002<a href='https://pubmed.ncbi.nlm.nih.gov/11885657/'>https://pubmed.ncbi.nlm.nih.gov/11885657/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A03AX11;
